Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial - Pouyiourou, Maria; Kraft, Bianca; Wohlfromm, Timothy; Stahl, Michael; Kubuschok, Boris; Löffler, Harald; Hacker, Ulrich T.; Hübner, Gerdt; Weiss, Lena; Bitzer, Michael; Ernst, Thomas; Schütt, Philipp; et al. (Nature Communications, 2023)
Gesehen am 17.05.2024